The 7th Edition Cancer Staging Manual introduces an important change in cancer staging for the prostate, incorporating the preferred use of the Gleason Score as a prognostic factor in the Anatomic Stage/Prognostic Groups. The course will detail this important change and explain why extraprostatic invasion with microscopic bladder neck invasion (T4) is now included with T3a anatomic stage group. The course will also highlight new and emerging prognostic factors related to prostate cancer staging, including new data elements that will be collected by registrars.
Target Audience: This program is intended for physicians and registrars.
1. Differentiate the changes to the grading system with the Gleason Score now preferred.
2. Identify the changes to the sites including microscopic bladder neck invasion changing from pT4 to pT3a.
3. Integrate the role of the prognostic factors and their incorporation in the Anatomic Stage/Prognostic Groups.
Financial support for the development of this presentation and webinar has been provided by the American Cancer Society. The information provided here does not necessarily represent the views of the American Cancer Society, Society Staff, or it's Board of Directors.
For registration support, please call 1-800-274-9390 or email email@example.com
If you would like to pay by check or register via telephone, please contact our Customer Support Group at 1-800-274-9390.
Sam S. Chang, MD
Vanderbilt University School of Medicine
Sam S. Chang, MD, is an associate professor in the Department of Urologic Surgery at Vanderbilt University School of Medicine in Nashville, Tennessee and also the chair of the AJCC Genitourinary Task Force.
Dr Chang earned his undergraduate degree at Princeton University and his medical degree from Vanderbilt University School of Medicine. He completed residencies in general surgery and urologic surgery at Vanderbilt University Medical Center, followed by a fellowship in urologic oncology at Memorial Sloan-Kettering Cancer Center in New York, New York. He is board certified by the American Board of Urology.
Dr Chang holds leadership positions with several professional organizations, including chair of the Genitourinary Task Force for the American Joint Committee on Cancer, regional leader of the Southeastern Section of the American Urological Association (AUA) Young Leadership Committee, member of the board of advisors for the Men's Health Network, chair of the Prostate Cancer Core Curriculum for the AUA, and facilitator of the Urologic Malignancy Follow-Up Guidelines Panel for the AUA. He is also a representative of the Society of Urologic Oncology for the American Joint Committee on Cancer, panel member for the Prostate Cancer Foundation Award Committee for the AUA, member of the Genitourinary Tumors Cancer Protocol Review Panel for the College of American Pathologists, member of the Bladder Cancer Advocacy Network Scientific Advisory Board, member of the AUA/European Association of Urology Academic Fellowship Committee, member of the Prostate Cancer Task Force - National Cancer Institute GU Steering Committee, abstract reviewer for the American Urological Association annual meeting, and panel member for the National Cancer Institute Prostate Cancer Task Force Genitourinary Steering Committee.
Dr Chang is a member of the American Association for Cancer Research, AUA, Society of Urologic Oncology, and American Association of Clinical Urologists. He has received several awards and is listed in Castle Connolly America's Top Doctors for Cancer, Best Doctors in America, Who's Who in America, and Who's Who in Medicine and Healthcare.
Dr Chang has been a principal investigator or subinvestigator for nearly 30 grant-supported research studies and has published more than 120 journal articles and 19 book chapters. He is an editorial board member for Family Urology, Prostate Cancer and Prostatic Diseases, and Postgraduate Medicine, and is a reviewer for numerous journals, including Cancer, Cancer Research, Journal of Urology, and International Journal of Cancer.
CE Credit: The National Cancer Registrars Association(NCRA) has determined that this program 2010-003G supports 1.0 CE Hours.
The American College of Surgeons is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medial education for physicians.
The American College of Surgeons designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.